\n\t\t\t
The market for PCVs is huge, there is enough room for at least five entities, said Pushpa Vijayaraghavan, vice-president of consulting firm Sathguru Inc.
\nIn India, there are 25 million babies born every year. Even by the most conservative of pricing estimates, it\u2019s a $500 million market, she explained.
\nIt\u2019s just matter of time before India introduces PCVs into its immunization programme, as it is already a GAVI-eligible country, Vijayaraghavan added.<\/p>\n\t\t<\/div>\n\t<\/div>\n[vc_column_text]Mosuvan Kuppusamy and his team of a dozen people, including molecular biologists and biochemists, are working in mission mode at Alexandria Knowledge Park on the outskirts of Hyderabad to get their pneumococcal conjugate vaccine (PCV) candidate into clinical trials, where the vaccine will be tested on humans for safety and efficacy.<\/p>\n
Their goal is to get the drug candidate into the trial stage in two months.<\/p>\n
After close to five-and-a-half years of toil and burning through Rs.6 crore, the 60-year-old scientist-turned-entrepreneur\u2019s Tergene Biotech Pvt. Ltd has been able to develop a potent vaccine candidate that provides protection against 15 bacterial sub-types of pneumonia, a disease that infects the lungs.<\/p>\n
The fledgling company that survived on Biotechnology Industry Research Assistance Council (Birac) funds and Kuppusamy\u2019s family silver, got a booster shot last year when Aurobindo Pharma Ltd, one of India\u2019s leading generic drug makers, decided to invest in it.<\/p>\n
Birac, under the department of biotechnology of the ministry of science and technology, has the mandate to strengthen and empower research capacities of biotech entrepreneurs and provide an enabling ecosystem.<\/p>\n
Aurobindo Pharma will fund the remainder of the vaccine development process that includes clinical trials, setting up a production plant and marketing the vaccine\u2014all of which may cost upwards of Rs.120 crore.<\/p>\n
\u201cThere is a huge unmet need for a pneumococcal vaccine and our vaccine is comprehensive and cost-effective,\u201d Kuppusamy said.<\/p>\n
If everything goes according to plan, Kuppusamy is confident that PCV will hit the market by 2018-end.<\/p>\n
Tergene is not alone in the race to make the pediatric vaccine. Big Indian vaccine names such as Pune-based Serum Institute of India Ltd and New Delhi-based Panacea Biotec Ltd are also developing PCVs.<\/p>\n
Serum and Panacea have received funding support from the Bill and Melinda Gates Foundation.<\/p>\n
Serum Institute\u2019s PCV has entered phase-2 trials, and is expected to take at least two years to hit the market. It is collaborating with global non-profit healthcare agency PATH for the speedy development of a 10-valent PCV, focusing on the serotypes or bacteria sub-types prevalent in 70.4% of the affected population in Asia, Africa, Latin America, and India, the Serum website said.<\/p>\n
\u201cIf phase-3 trials are positive, it\u2019s a game-changer vaccine,\u201d said Suresh Jadhav, executive director of Serum.<\/p>\n
Panacea Biotec\u2019s 10-valent PCV has entered phase-2 and phase-3 studies simultaneously. \u201cSo far, the clinical outcome is very promising,\u201d said an executive of Panacea, who didn\u2019t want to be named.<\/p>\n
The executive declined to share more details. Rajesh Jain, managing director of Panacea Biotec, couldn\u2019t be reached for a comment.<\/p>\n
Panacea Biotec has ramped up its production capacity to supply 4 million doses of PCV in anticipation of the vaccine\u2019s rollout and has been trying to get a partner to fund phase-3 trials, said an expert who closely tracks the vaccine industry and didn\u2019t want to be named, citing his company\u2019s policy.<\/p>\n
The Panacea vaccine could be the first to hit the market, the expert said.<\/p>\n
To be sure, Indian companies are pitted against formidable rivals in the form of US-based Pfizer Inc. and UK-based GlaxoSmithKline Plc. (GSK), which already have pneumococcal vaccines in the market.<\/p>\n
Pfizer\u2019s PCVs Prevnar7 and Prevnar13 are blockbusters, with sales of $4.5 billion globally in the year ended December 2014, while GSK\u2019s Synflorix posted sales of \u00a3398 million ($620 million).<\/p>\n
Pfizer\u2019s Prevnar13 is the most widely prescribed vaccine by paediatricians and provides protection against 13 types of bacteria causing pneumonia, while GSK\u2019s Synflorix provides protection against 10 types of bacteria.<\/p>\n
Not to be left out, US-based Merck and Co. and France-based Sanofi SA have also joined the race to develop new PCVs, which are in various stages of clinical development.<\/p>\n
Why the rush for a pneumonia vaccine?<\/p>\n
According to a study funded by the Bill and Melinda Gates Foundation, published in medical journal Lancet in October 2014, of the 6.3 million children who died in their first five years of life in 2013, 51.8% (3.26 million) died of infections. Pneumonia caused close to a million deaths, or 15% of the total.<\/p>\n
The three leading causes of under-5 deaths in India are pre-term birth complications, pneumonia and intrapartum complications. Pneumonia and diarrhoea accounted for 297,114 deaths in India.<\/p>\n
\u201cMost of the deaths related to pneumonia are preventable,\u201d said P. Sudarshan Reddy, senior paediatrician and researcher. Reddy heads Hyderabad\u2019s Niloufer Hospital, which is one of the largest publicly-funded maternity and paediatrics hospitals in India.<\/p>\n
\u201cThe cost of the vaccine remains a major barrier in our fight against pneumonia in India,\u201d Reddy said, adding, \u201cHere is where Indian vaccine companies can make a difference.\u201d<\/p>\n
Pfizer\u2019s Prevnar13 costs about Rs.3,800 per dose, while GSK\u2019s Synflorix is priced at around Rs.2,000-2,200. In addition to the administering cost by the physician, a child needs at least three primary doses to get protection against pneumonia\u2014taking the cost of the vaccine to Rs.11,400 and Rs.6,000-6,600, respectively, making it the costliest vaccine in the immunization schedule of a child.<\/p>\n
Some pediatricians suggest an additional PCV booster as well.<\/p>\n
India is yet to introduce PCV as part of its universal immunization programme. Globally, pneumococcal vaccines have been introduced in 117 countries and 58 of those countries are eligible for GAVI funding.<\/p>\n
GAVI, or the Global Alliance for Vaccines and Immunisation, has raised $1.5 billion from donors as advance market commitment funds to supply PCVs. The alliance procured a total of 100 million doses of PCV in 2014 and has contracted the supply of 1.46 billion doses, till 2024. Pfizer and GSK have been allocated $1.095 billion of the funds. Pfizer and GSK charge GAVI $10 per child for three doses.<\/p>\n
On top of this price paid to the companies, for a certain percentage of the doses sold to GAVI, they get an additional top-up subsidy on the base price, which makes it $7 per dose (or $21 per child).<\/p>\n
Pfizer and GSK are under pressure from advocacy groups such as M\u00e9decins Sans Fronti\u00e8res (MSF) to reduce prices of PCVs.<\/p>\n
\u201cThe high price of the PCV means that governments aren\u2019t able to afford its introduction in their public immunization programme, and therefore children aren\u2019t being protected against pneumonia,\u201d said Kate Elder, vaccines policy adviser at MSF.<\/p>\n
\u201cJust as a comparison, the pneumonia vaccine at its lowest global price (GAVI price) is currently 70% more expensive than the measles vaccine (also bought by GAVI),\u201d Elder said.<\/p>\n
MSF has started a campaign urging Pfizer and GSK to lower the price of PCVs to $5 per child.<\/p>\n
\u201cPfizer and GSK, the only two companies producing the PCV, have made more than $30 billion so far on sales of these vaccines. We think that it\u2019s safe to say that they can afford to drop the price,\u201d MSF said.<\/p>\n
Both Serum and Panacea have made commitments to supply PCVs to GAVI. Serum has pledged to sell the product at $6 per child ($2 per dose) to GAVI, and says that it will still make a profit. There is no information available publicly regarding Panacea\u2019s pricing commitment.<\/p>\n
Analysts say even discounting the lucrative private market, where Indian vaccine companies aren\u2019t too strong, there is still a lot of money to be made on sale of PCVs to mass immunization programmes.<\/p>\n
The market for PCVs is huge, there is enough room for at least five entities, said Pushpa Vijayaraghavan, vice-president of consulting firm Sathguru Inc.<\/b><\/p>\n
In India, there are 25 million babies born every year. Even by the most conservative of pricing estimates, it\u2019s a $500 million market, she explained.<\/b><\/p>\n
It\u2019s just matter of time before India introduces PCVs into its immunization programme, as it is already a GAVI-eligible country, Vijayaraghavan added.<\/b><\/p>\n
But there are technical and financial viability challenges to development of PCVs.<\/p>\n
\u201cPCV clinical trial is a very tricky thing,\u201d said Jadhav of Serum Institute.<\/p>\n
\u201cYou have to do it (clinical trials) in adults first, followed by toddlers, and then infants, unlike other vaccines where you can directly go to infants. As there are 10 different serotypes, you have to check for each serotype…whether it\u2019s working,\u201d Jadhav said, explaining the complexity of the vaccine.<\/p>\n
\u201cIt\u2019s a very complex vaccine to manufacture,\u201d said K. Anand Kumar, deputy managing director at Hyderabad-based Indian Immunologicals Ltd, which makes animal and human vaccines.<\/p>\n
\u201cWhen you say pentavalent, it\u2019s just 5 serotypes, whereas this is a 10-15 valent vaccine that means 10-15 different serotypes of pneumococci have to be grown, purified and made into a vaccine, so stability of the vaccine is a major factor,\u201d Kumar pointed out.<\/p>\n
Krishna Ella, chairman of vaccine maker Bharat Biotech International Ltd, takes a cautious line on PCV.<\/p>\n
\u201cPfizer and GSK have already brought down the prices to $3.30-3.5 per dose for GAVI. There is scope for further price erosion,\u201d said Ella.<\/p>\n
Hyderabad-based Bharat Biotech, which successfully developed a vaccine against childhood diarrhoea and offered it at $1 per dose, has stayed away from PCV so far.<\/p>\n
Source: live mint <\/a>[\/vc_column_text][\/vc_column][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"[vc_row][vc_column][vc_column_text]Mosuvan Kuppusamy and his team of a dozen people, including molecular biologists and biochemists, are working in mission mode at Alexandria Knowledge Park on the outskirts of Hyderabad to get their pneumococcal conjugate vaccine (PCV) candidate into clinical trials, where the vaccine will be tested on humans for safety and efficacy. Their goal is to […]<\/p>\n","protected":false},"author":1,"featured_media":235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-234","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare"],"yoast_head":"\n
Pneumonia vaccine: the new battleground for Indian drug makers<\/title>\n<meta name=\"description\" content=\"The market for PCVs is huge, there is enough room for at least five entities, said Pushpa Vijayaraghavan, vice-president of consulting firm Sathguru Inc.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pneumonia vaccine: the new battleground for Indian drug makers\" \/>\n<meta property=\"og:description\" content=\"The market for PCVs is huge, there is enough room for at least five entities, said Pushpa Vijayaraghavan, vice-president of consulting firm Sathguru Inc.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/\" \/>\n<meta property=\"og:site_name\" content=\"Sathguru News\" \/>\n<meta property=\"article:published_time\" content=\"2016-03-31T08:28:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-02T06:46:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/indian-drug-makers.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"621\" \/>\n\t<meta property=\"og:image:height\" content=\"414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"sadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@sathgurumc\" \/>\n<meta name=\"twitter:site\" content=\"@sathgurumc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"sadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pneumonia vaccine: the new battleground for Indian drug makers","description":"The market for PCVs is huge, there is enough room for at least five entities, said Pushpa Vijayaraghavan, vice-president of consulting firm Sathguru Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/","og_locale":"en_US","og_type":"article","og_title":"Pneumonia vaccine: the new battleground for Indian drug makers","og_description":"The market for PCVs is huge, there is enough room for at least five entities, said Pushpa Vijayaraghavan, vice-president of consulting firm Sathguru Inc.","og_url":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/","og_site_name":"Sathguru News","article_published_time":"2016-03-31T08:28:02+00:00","article_modified_time":"2021-04-02T06:46:29+00:00","og_image":[{"width":621,"height":414,"url":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/indian-drug-makers.jpg","type":"image\/jpeg"}],"author":"sadmin","twitter_card":"summary_large_image","twitter_creator":"@sathgurumc","twitter_site":"@sathgurumc","twitter_misc":{"Written by":"sadmin","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/#article","isPartOf":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/"},"author":{"name":"sadmin","@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/person\/3e1fb591be3f42bc88c681ee61ab007a"},"headline":"Pneumonia vaccine: the new battleground for Indian drug makers","datePublished":"2016-03-31T08:28:02+00:00","dateModified":"2021-04-02T06:46:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/"},"wordCount":1579,"commentCount":0,"publisher":{"@id":"https:\/\/www.sathguru.com\/news\/#organization"},"image":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/indian-drug-makers.jpg","articleSection":["Healthcare"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/","url":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/","name":"Pneumonia vaccine: the new battleground for Indian drug makers","isPartOf":{"@id":"https:\/\/www.sathguru.com\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/#primaryimage"},"image":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/indian-drug-makers.jpg","datePublished":"2016-03-31T08:28:02+00:00","dateModified":"2021-04-02T06:46:29+00:00","description":"The market for PCVs is huge, there is enough room for at least five entities, said Pushpa Vijayaraghavan, vice-president of consulting firm Sathguru Inc.","breadcrumb":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/#primaryimage","url":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/indian-drug-makers.jpg","contentUrl":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/indian-drug-makers.jpg","width":621,"height":414},{"@type":"BreadcrumbList","@id":"https:\/\/www.sathguru.com\/news\/2016\/03\/31\/pneumonia-vaccine-the-new-battleground-for-indian-drug-makers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sathguru.com\/news\/"},{"@type":"ListItem","position":2,"name":"Pneumonia vaccine: the new battleground for Indian drug makers"}]},{"@type":"WebSite","@id":"https:\/\/www.sathguru.com\/news\/#website","url":"https:\/\/www.sathguru.com\/news\/","name":"Sathguru News","description":"Sathguru News","publisher":{"@id":"https:\/\/www.sathguru.com\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sathguru.com\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.sathguru.com\/news\/#organization","name":"sathguru Management Consultants","url":"https:\/\/www.sathguru.com\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Sathguru-logo.png","contentUrl":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Sathguru-logo.png","width":180,"height":83,"caption":"sathguru Management Consultants"},"image":{"@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/sathgurumc","https:\/\/www.linkedin.com\/company\/sathguru-management-consultants","https:\/\/www.youtube.com\/user\/SathguruConsultants"]},{"@type":"Person","@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/person\/3e1fb591be3f42bc88c681ee61ab007a","name":"sadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/028fee43c618fecdf419f8b5e2b991874271dfa82e49a8fc0ff51997d3c1ee41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/028fee43c618fecdf419f8b5e2b991874271dfa82e49a8fc0ff51997d3c1ee41?s=96&d=mm&r=g","caption":"sadmin"}}]}},"_links":{"self":[{"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/posts\/234","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/comments?post=234"}],"version-history":[{"count":3,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/posts\/234\/revisions"}],"predecessor-version":[{"id":1744,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/posts\/234\/revisions\/1744"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/media\/235"}],"wp:attachment":[{"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/media?parent=234"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/categories?post=234"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/tags?post=234"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}